glp 1 agonist uses Frontiers Glucagon-Like Peptide-1 Receptor Agonist Use

Abbreviations List: Funding No funding has been received for this manuscript Conflicts of Interest The author declares no conflict of interest References 1.Ogurtsova K., da Rocha Fernandes J.D., Huang Y., Linnenkamp U., Guariguata L., Cho N.H., Cavan D., Shaw J.E., Makaroff L.E

H., & Dailey, M

Adderley NJ, Subramanian A, Nirantharakumar K, et al

Additional well-designed, prospective studies are needed to confirm the potential benefit of GLP-1 receptor agonist treatment for patients with advanced CKD or ESKD." For further information: DOI: 10.1001/jamanetworkopen.2022.1169 Keywords: CKD, ESKD, GLP-1 receptor agonist, DPP-4 inhibitors, type 2 diabetes, JAMA Network Open, chronic kidney disease, end-stage kidney disease, National Health Insurance Research Database of Taiwan, MACCE, Mortality rate